Clinical Trial Modernization Act
- Bill Number
- S. 4440
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 2
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2026-04-29: Read twice and referred to the Committee on Finance.
- Last Updated
- 2026-05-21T20:00:31Z
AI-Generated Summary
Purpose
The Clinical Trial Modernization Act aims to update clinical trials by reducing participation barriers, particularly for underrepresented populations (groups with historically low trial involvement, as defined by NIH and FDA guidelines), to improve diversity in studies for drugs, devices, and vaccines.
Key Provisions
- Grants for Outreach (Sec. 3): Authorizes HHS Secretary to award grants/contracts for community education, training healthcare workers, stakeholder engagement, and partnerships to recruit underrepresented groups into trials for diseases disproportionately affecting them. Priorities include multilingual materials and outreach in tribal/rural areas. Funding authorized for FY 2027-2028.
- Safe Harbor for Participant Expenses (Sec. 4): Amends Social Security Act's Anti-Kickback Statute (AKS) and Civil Monetary Penalties Law (CMP Law) to allow trial sponsors to pay participants' non-medical expenses (e.g., travel, meals) and provide free digital health technologies (e.g., apps or devices needed for trial participation), if available to all and aimed at including diverse demographics, including rural communities.
- Sponsor Payment of Cost-Sharing (Sec. 5): Permits drug/device makers to cover patients' out-of-pocket costs (cost-sharing, like deductibles under Medicare/Medicaid) without violating AKS, CMP Law, or False Claims Act, subject to safeguards: must align with federal program rules, be reasonable for diversity/retention, available throughout trial, non-contingent on future purchases, capped at actual costs, with patient agreements and enrollment limits.
- Tax Exclusion for Participants (Sec. 6): Adds Internal Revenue Code §139J, excluding up to $2,000 per year of trial sponsor payments from participants' gross income (not taxable).
- Rule of Construction (Sec. 7): Clarifies these changes do not limit other existing legal protections for trial participation incentives.
Significant Changes to Existing Law
- Anti-Kickback and CMP Law Amendments (Secs. 4-5): Expands statutory exceptions (safe harbors) to explicitly permit expense reimbursements, digital tools, and cost-sharing payments—previously risky under fraud/abuse laws—to promote trial diversity without penalties.
- New Tax Benefit (Sec. 6): Introduces first-of-its-kind federal tax exclusion specifically for clinical trial compensation, capped at $2,000/year.
- New Grant Program (Sec. 3): Creates dedicated funding for diversity-focused recruitment, building on but distinct from existing NIH/FDA efforts.
Potential Impacts
- Government Agencies: HHS (FDA, CMS, NIH) gains grant authority and enforcement discretion; increased oversight for compliance with new safe harbors; modest short-term spending (FY 2027-2028).
- Citizens: Lowers financial hurdles for trial participation (e.g., travel, copays), especially for underrepresented, low-income, rural, or minority groups; potential for more diverse data leading to better-generalized treatments; tax savings up to $2,000/year for participants.
- International Relations: None directly addressed.
Main Stakeholders Affected
- Underrepresented Populations: Primary beneficiaries via easier access and reduced costs.
- Trial Participants: All gain from expense coverage and tax relief.
- Sponsors (Drug/Device Manufacturers): Can offer incentives without legal risk, aiding recruitment/diversity plans.
- Healthcare Providers/Investigators: Training opportunities; must follow protocols and agreements.
- Federal Health Programs (Medicare/Medicaid): Assured coverage consistency; safeguards against excess costs/utilization.
- Taxpayers: Fund grants; benefit from improved trial outcomes.
Notable Legal, Constitutional, or Political Implications
- Legal: Strengthens fraud protections with detailed safeguards (e.g., enrollment caps, no advertising) while broadening safe harbors under AKS/CMP/False Claims Act; applies immediately to new payments post-enactment.
- Constitutional: No apparent issues; aligns with Congress's spending and commerce powers.
- Political: Bipartisan sponsorship; promotes health equity without mandating changes, focusing on voluntary incentives and existing diversity requirements (e.g., FDA plans).
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (1)
Recent Actions
- 2026-04-29: Read twice and referred to the Committee on Finance.
- 2026-04-29: Introduced in Senate
Bill Versions
- Clinical Trial Modernization Act — issued 2026-04-29 — PDF (11 pages)